Vor Biopharma Inc (VOR) Stock Price, Quote & News

Company Profile

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 655 6580

Website: www.vorbio.com

Address:

100 Cambridgepark Drive, Suite 101, Cambridge, United States

GiddyLambo Nov. 14 at 6:18 PM

$VOR I’m holding NXXT because earnings could print today and the unfair multiple is the opportunity and Forefront 501,000 ≈ $1.00M and UBS 43,870 ≈ $87.7K loaded before headlines and I want to sit with them

0 · Reply

JarvisFlow Nov. 14 at 12:51 PM

HC Wainwright & Co. has updated their rating for Vor Biopharma ( $VOR ) to Buy with a price target of 32.

0 · Reply

SquidGainz Nov. 13 at 11:35 PM

$VOR $BIAF $ECDA $ATHA 0

0 · Reply

d_risk Nov. 13 at 9:49 PM

$VOR - Vor Biopharma Inc. Common Stock - 10Q - Updated Risk Factors VOR’s latest 10-Q flags deepening losses ($2.4B YTD), extended cash runway, and ongoing heavy spending with no marketed products; risks now detail clinical, regulatory, and commercialization hurdles for telitacicept, dilution from recent financings, manufacturing and tax complexities, expanded competition, and new concerns over data, healthcare law, and major shareholder control. #Biopharma #HealthcareLaw #FinancialLosses #RegulatoryChallenges #ClinicalRisk 🟢 Added 🟠 Removed https://d-risk.ai/VOR/10-Q/2025-11-13

0 · Reply

Livinglifewithlivingston Nov. 13 at 9:42 PM

$VOR lost 812.7 million is trash

0 · Reply

Livinglifewithlivingston Nov. 13 at 9:40 PM

$VOR terrible news

0 · Reply

Stocktalk333 Nov. 13 at 6:18 PM

$VOR Curious…why are so many people posting about NXXT on this ticker? Is there a connection?

1 · Reply

ThadXTrader Nov. 13 at 5:21 PM

$VOR I used to chase volume. Now I watch filings. NXXT has 48 institutions quietly locking up float. CEO bought 1M shares personally — not options, not restricted stock — open-market cash. Retail still hesitating because it’s “too quiet.” I love quiet. Quiet is where wealth starts. Friday’s ER will make it loud.

0 · Reply

Livinglifewithlivingston Nov. 13 at 4:44 PM

$VOR

0 · Reply

AmaBagz Nov. 13 at 2:03 PM

$VOR I see NXXT as deeply undervalued and earnings can be today so I am following BlackRock 582,422 and Mirae 9,529 into the trade

0 · Reply

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 11, 2025, 9:43 AM EST - 3 days ago

Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial

Nov 10, 2025, 9:56 PM EST - 3 days ago

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

Nov 10, 2025, 4:01 PM EST - 4 days ago

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

Nov 8, 2025, 11:45 AM EST - 6 days ago

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Nov 7, 2025, 8:00 AM EST - 7 days ago

Vor Bio to Participate in Upcoming Investor Conferences

Nov 3, 2025, 8:00 AM EST - 11 days ago

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

Oct 31, 2025, 4:30 PM EDT - 14 days ago

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 29, 2025, 11:01 AM EDT - 16 days ago

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

Oct 22, 2025, 4:30 PM EDT - 23 days ago

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease

Oct 17, 2025, 8:00 AM EDT - 4 weeks ago

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025

Oct 16, 2025, 8:00 AM EDT - 4 weeks ago

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

Oct 14, 2025, 8:00 AM EDT - 4 weeks ago

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren's Disease at ACR 2025

Sep 29, 2025, 7:00 AM EDT - 6 weeks ago

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025

Sep 25, 2025, 11:48 AM EDT - 7 weeks ago

Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise

Sep 23, 2025, 8:00 AM EDT - 7 weeks ago

Vor Bio Appoints Navid Z. Khan, Ph.D.

Sep 17, 2025, 9:00 PM EDT - 2 months ago

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

Sep 17, 2025, 4:15 PM EDT - 2 months ago

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

Sep 12, 2025, 4:15 PM EDT - 2 months ago

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 2, 2025, 8:00 AM EDT - 2 months ago

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Aug 27, 2025, 8:00 AM EDT - 2 months ago

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

Aug 13, 2025, 11:15 AM EDT - 3 months ago

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

Aug 13, 2025, 8:30 AM EDT - 3 months ago

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Aug 4, 2025, 8:30 AM EDT - 3 months ago

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

Jul 21, 2025, 8:30 AM EDT - 4 months ago

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Jul 18, 2025, 4:00 PM EDT - 4 months ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 17, 2025, 8:30 AM EDT - 4 months ago

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Jul 10, 2025, 4:00 PM EDT - 4 months ago

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Jul 1, 2025, 4:00 PM EDT - 4 months ago

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2025, 2:31 PM EDT - 4 months ago

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

Jun 25, 2025, 4:50 PM EDT - 5 months ago

Vor Bio Announces $175 Million Private Placement

Jun 25, 2025, 4:45 PM EDT - 5 months ago

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

May 8, 2025, 8:30 AM EDT - 6 months ago

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Mar 20, 2025, 4:05 PM EDT - 8 months ago

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Feb 13, 2025, 8:00 AM EST - 9 months ago

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Feb 3, 2025, 8:00 AM EST - 10 months ago

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 9:00 AM EST - 11 months ago

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Dec 27, 2024, 9:00 AM EST - 11 months ago

Vor Bio Announces $55.6 Million Private Placement

Dec 9, 2024, 7:30 AM EST - 1 year ago

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

Sep 6, 2024, 9:35 AM EDT - 1 year ago

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

Sep 5, 2024, 4:01 PM EDT - 1 year ago

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

May 9, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

May 2, 2024, 4:01 PM EDT - 1 year ago

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

Mar 20, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Feb 7, 2024, 8:00 AM EST - 1 year ago

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 17, 2024, 4:01 PM EST - 1 year ago

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

Nov 27, 2023, 8:00 AM EST - 2 years ago

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

Nov 9, 2023, 4:01 PM EST - 2 years ago

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

GiddyLambo Nov. 14 at 6:18 PM

0 · Reply

JarvisFlow Nov. 14 at 12:51 PM

HC Wainwright & Co. has updated their rating for Vor Biopharma ( $VOR ) to Buy with a price target of 32.

0 · Reply

SquidGainz Nov. 13 at 11:35 PM

$VOR $BIAF $ECDA $ATHA 0

0 · Reply

d_risk Nov. 13 at 9:49 PM

0 · Reply

Livinglifewithlivingston Nov. 13 at 9:42 PM

$VOR lost 812.7 million is trash

0 · Reply

Livinglifewithlivingston Nov. 13 at 9:40 PM

$VOR terrible news

0 · Reply

Stocktalk333 Nov. 13 at 6:18 PM

$VOR Curious…why are so many people posting about NXXT on this ticker? Is there a connection?

1 · Reply

ThadXTrader Nov. 13 at 5:21 PM

0 · Reply

Livinglifewithlivingston Nov. 13 at 4:44 PM

$VOR

0 · Reply

AmaBagz Nov. 13 at 2:03 PM

$VOR I see NXXT as deeply undervalued and earnings can be today so I am following BlackRock 582,422 and Mirae 9,529 into the trade

0 · Reply

Dav89 Nov. 12 at 9:47 PM

$VOR WHAT IS THE STORY WITH VOR?

1 · Reply

Otis_Lloyd_ Nov. 12 at 5:33 PM

$VOR AA detection is the battleground: Mainz Biomed ~82% vs ~43% Cologuard Plus and ~13% Shield; CRC stays ~97/97. Maxim boosts institutional interest, GARPS cements clinical use, MEDICA closes distribution. Analysts mark it at $14 PT.

0 · Reply

elmono Nov. 11 at 10:31 PM

$VOR buying the shit out of this. One of the most undervalued tickers out there

1 · Reply